Perspective TherapeuticsCATX
About: Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Employees: 140
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
58% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 31
50% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 24
6% more funds holding
Funds holding: 127 [Q3] → 134 (+7) [Q4]
2.96% less ownership
Funds ownership: 72.86% [Q3] → 69.9% (-2.96%) [Q4]
37% less call options, than puts
Call options by funds: $331K | Put options by funds: $527K
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
77% less capital invested
Capital invested by funds: $655M [Q3] → $151M (-$505M) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Robert Burns 15% 1-year accuracy 26 / 171 met price target | 388%upside $10 | Buy Reiterated | 31 Mar 2025 |
RBC Capital Gregory Renza 0 / 0 met price target | 632%upside $15 | Outperform Maintained | 27 Mar 2025 |
Wedbush David Nierengarten 34% 1-year accuracy 39 / 116 met price target | 437%upside $11 | Outperform Reiterated | 27 Mar 2025 |
Scotiabank Louise Chen 32% 1-year accuracy 43 / 133 met price target | 632%upside $15 | Sector Outperform Initiated | 7 Mar 2025 |
Financial journalist opinion
Based on 5 articles about CATX published over the past 30 days



![Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma](https://wsr-news.imgdelivr.io/w9BCebpe.jpg?w=640&h=360)




![Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium](https://wsr-news.imgdelivr.io/8y1uvyiD.jpg?w=640&h=360)
